KW-6356

KW-6356

Selective A2A receptor antagonist researched for CNS signaling, dopaminergic pathway modulation,
neuroinflammatory response, and movement-related research models.

Overview

KW-6356 is a selective adenosine A2A receptor antagonist studied in advanced neurological
and neurodegenerative research settings. The A2A receptor is heavily involved in neurotransmission,
motor signaling, basal ganglia activity, and dopaminergic pathway regulation, making KW-6356 a
compound of interest for CNS-focused laboratory research.

Scientific Background

Adenosine A2A receptors are primarily expressed in areas of the brain associated with movement
control, reward signaling, and neuronal communication. In research models, excessive A2A receptor
activity has been associated with reduced dopaminergic signaling efficiency, altered motor output,
and increased inflammatory signaling within the central nervous system.

As an A2A receptor antagonist, KW-6356 is studied for its ability to block A2A receptor activity
and support investigation into how adenosine signaling interacts with dopamine pathways,
neuroinflammation, and movement-related cellular mechanisms.

Research Applications

• Investigation of adenosine A2A receptor signaling
• Dopaminergic pathway and basal ganglia research
• Neuroinflammation and oxidative stress pathway studies
• Movement-related and neurodegenerative research models
• CNS receptor interaction and neurotransmission studies

Storage & Handling

Store in a cool, dry, controlled laboratory environment. Avoid excessive heat, moisture,
and direct light exposure. Handle only using proper laboratory procedures and appropriate
research safety protocols.

For Laboratory Research Use Only

This product is intended strictly for laboratory research purposes only. Not for human or animal
consumption. Not for medical, diagnostic, therapeutic, dietary, or household use. This product is
not intended to diagnose, treat, cure, or prevent any disease.